NIH Keeps Potential Dangerous Gain-of-Function Research Paused Under New 2026 Policy

Status: Confirmed U.S. government policy and current NIH funding pause. The policy is not proof that Anthony Fauci or any other person committed a crime. Separate claims about earlier research remain claims unless supported by a court finding or equivalent adjudicated record. Source dates: July 28-29, 2026. Last reviewed: August 7, 2026.

NIH Keeps Potential Dangerous Gain-of-Function Research Paused Under New 2026 Policy

The National Institutes of Health says all potential dangerous gain-of-function research remains paused while agencies implement a new government-wide policy for stopping high-risk life-sciences research. NIH posted the policy notice July 28 and explained the rollout July 29. The White House policy creates new definitions, review responsibilities, and timelines for projects that could create or modify biological agents in ways that pose serious risks.

This is a real policy change and a legitimate Fauci-era accountability follow-up. It shows that the federal government now considers the previous oversight structure insufficient for some high-risk work. It does not, by itself, prove that Anthony Fauci funded the creation of COVID-19, lied under oath, or committed a crime. Those are separate allegations that require separate evidence and legal findings.

BadPD’s standard is simple: publish the policy as confirmed, publish official allegations as official claims, attach opposing or limiting records, and refuse to turn a political narrative into a conviction that no court has issued.

What NIH announced

NIH Notice NOT-OD-26-101 says potential dangerous gain-of-function research remains paused until NIH has implementation requirements in place. The notice describes dangerous gain-of-function research, or DGOF, and an Independent Research Oversight Commission, or IROC, that will review covered work.

The government policy gives agencies 120 days to issue implementation guidance and calls for an independent third-party review body within 90 days. Those deadlines create a testable public record. Agencies should not be allowed to announce a strict policy and then quietly delay the procedures, staffing, conflict rules, and project decisions needed to enforce it.

NIH Director Jay Bhattacharya described the policy as a safety and security measure. That is an official policy position, not independent proof that every covered project is dangerous or that every earlier decision was reckless. The details will matter: which experiments are screened, who makes the decision, what evidence is public, what appeals exist, and how overseas work is monitored.

What “paused” means

A pause is not a permanent ban on all virology or infectious-disease research. It is a funding and review hold for work that may fall within the new dangerous gain-of-function category while implementation rules are established. Routine, low-risk, diagnostic, vaccine, surveillance, and basic research should not be carelessly branded as DGOF merely because it involves a pathogen.

At the same time, agencies should not evade the policy by using narrow labels, pass-through grants, subawards, overseas partners, or contract structures. Review should follow the actual experiment and its reasonably foreseeable capabilities, not just the title on a grant application.

The policy needs a transparent screening funnel. NIH should report how many proposals were screened, how many required enhanced review, how many were paused, modified, approved, denied, or referred to another agency. Project-specific details may require redaction for security or proprietary reasons, but aggregate performance and decision standards should be public.

Why this belongs in the Fauci records ledger

Anthony Fauci led the National Institute of Allergy and Infectious Diseases during the period now under intense congressional and intelligence-community scrutiny. Senate hearings, NIH grant records, GAO reviews, and executive-branch releases continue to drive disputes about U.S.-funded research, subawards, the Wuhan Institute of Virology, and what officials knew.

The new policy is relevant because it changes the government’s approach to high-risk research. It can be compared with prior rules, prior grant-review decisions, and sworn testimony. That comparison should focus on documents: grant applications, progress reports, subaward terms, experiment descriptions, agency correspondence, review minutes, funding decisions, and testimony transcripts.

Policy change is not retroactive proof of guilt. Governments revise aviation, financial, laboratory, and cybersecurity rules after weaknesses become visible. A stricter rule can confirm that leaders see a risk. It does not automatically establish that a named official knowingly violated the previous rule or caused a specific event.

The ODNI claim still requires independent testing

The Office of the Director of National Intelligence issued a June 2026 release asserting that Fauci funded Wuhan laboratory research that sparked COVID-19. That is an extraordinary official claim. It deserves publication as a claim made by ODNI and scrutiny of the documents ODNI cites. It is not a court judgment, criminal charge, or scientific consensus merely because an intelligence office wrote the headline.

The public needs the underlying records, chain of custody, analytic confidence, dissenting views, and explanation of what is direct evidence versus inference. If documents are classified, Congress should press for lawful declassification or a detailed unclassified explanation. If the claim changes, ODNI should maintain a correction and update ledger.

Fauci’s testimony and response also must remain attached. A records desk should not erase a subject’s denial or limiting evidence. The right question is not which political team produced the loudest clip. It is whether primary records establish the funding path, experimental work, knowledge, representations, and causation claimed.

What the new review body must disclose

The Independent Research Oversight Commission will only be credible if its membership, conflict rules, recusal record, expertise, decision criteria, and meeting cadence are public. Members should include biosafety, biosecurity, virology, epidemiology, public health, national security, ethics, and public-interest expertise. Financial and institutional conflicts need meaningful disclosure.

The commission also needs a written standard for overseas projects. Federal agencies should identify prime recipients, subrecipients, laboratories, countries, agents, experimental aims, containment levels, and inspection rights. If an overseas partner will not provide records or site access, U.S. taxpayers should not be expected to fund high-risk work on trust alone.

Approval decisions should include conditions, monitoring schedules, incident-reporting duties, and stop-work triggers. Denials should explain the safety basis without publishing operational details that create a new risk. Modified projects should show which experiment or capability was removed.

Congress needs an implementation clock

The policy gives agencies deadlines. Congress should post a public implementation clock for NIH, the Department of Health and Human Services, the Department of Defense, and any other agency funding covered work. Each agency should identify its guidance date, designated officials, inventory of paused projects, review backlog, and expected decision timeline.

Inspectors general should audit whether agencies and recipients correctly identified covered work. A self-reporting system without independent testing invites narrow interpretations. Audits should examine grant language, lab protocols, progress reports, publications, subawards, and changes made after approval.

Whistleblower channels are also necessary. Laboratory staff, grant administrators, and contractors need a protected way to report work that differs from an approved protocol. Retaliation allegations should be tracked and resolved without exposing sensitive scientific details or personal information.

Confirmed, claimed, disputed, and pending

• Confirmed: NIH posted NOT-OD-26-101 on July 28, 2026, and says all potential dangerous gain-of-function research remains paused pending NIH implementation requirements.
• Confirmed: The government policy calls for agency implementation guidance within 120 days and an independent third-party review body within 90 days.
• Confirmed: Executive Order 14292, issued in May 2025, directed the development of a new approach to high-risk biological research.
• Official claim, not adjudicated fact: ODNI’s June 2026 assertion about Fauci, Wuhan research, and the origin of COVID-19.
• Not established by this policy: Criminal conduct by Fauci or another official, the laboratory origin of COVID-19, or causation by a particular U.S.-funded experiment.
• Pending: Agency guidance, commission membership, review criteria, project inventories, individual funding decisions, and independent audits of compliance.

The accountability standard

America should support scientific work that protects people from disease. It should not outsource high-risk experiments, hide them behind pass-through funding, or ask taxpayers to accept unverified assurances. The new policy can improve safety if agencies enforce it against the actual work and publish enough receipts for independent review.

Fauci accountability should follow the same rule. Put the testimony beside the grants. Put the ODNI claims beside the underlying documents and dissent. Put old policy beside new policy. Label every allegation and update every outcome. That is stronger than either worship or scapegoating because it gives the public a record that can survive political turnover.

A plain-language implementation checklist

The first test is the project inventory. Each funding agency should count all active grants, contracts, and subawards that may fall under the new rule. It should include work inside and outside the United States. The count should list how many projects are paused, under review, modified, approved, or denied. A total count can be public even when some project details must stay protected.

The second test is the screen. Agencies need one written set of questions. What agent is involved? What change is planned? Could the work increase spread, severity, host range, resistance, or immune escape? What safety level applies? What is the public-health benefit? Is there a safer way to answer the same question? The screen should follow the experiment, not the marketing name of the grant.

The third test is independent review. Reviewers should not judge a project when they have a financial, professional, or institutional conflict. Recusals should be logged. The commission should explain its vote rule. It should state when outside experts were used. It should keep minutes that can later be released with lawful redactions.

The fourth test is a clear decision. An approval should state the conditions. A modification should state what changed. A denial should state the safety reason in a way that does not publish dangerous details. Each decision should have a review date. High-risk work should not receive an open-ended approval that no one revisits.

Oversight does not end when a grant is approved

Research can change after an award. A lab may alter a method. A subrecipient may move work. New data may reveal a risk that was not clear at first. The oversight system needs change-control rules. A material change should trigger new review before the work proceeds.

Incident reporting also needs a deadline. Agencies should define which lab events require notice and how fast that notice must occur. They should track exposure, containment failure, missing material, record gaps, and work outside an approved protocol. Public summaries can protect security while still showing the number and type of events.

Site access is another basic test. If U.S. money supports covered work, the funding agreement should provide access to records and the site. A foreign or domestic partner that refuses lawful review should not keep receiving funds for high-risk work. Waivers, if any, should be rare, written, and visible to Congress.

How to judge the new policy one year from now

A year after implementation, the government should publish results. How many projects were screened? How many were paused? How many were changed or denied? How long did reviews take? How many conflicts led to recusal? How many incidents were reported? How many sites were inspected? How many recipients failed to provide records?

Those numbers will not answer every origin question. They will show whether the new policy is real. If agencies publish only a policy PDF and no results, the reform will be a press release. If they publish decisions, audits, and corrections, the public can measure it.

The same rule applies to the Fauci dispute. Claims should move through a dated evidence ledger. A new document should be linked. A changed claim should be corrected. A missing record should stay marked missing. That process is slower than a viral accusation. It is also far more useful.

Sources

• NIH Notice NOT-OD-26-101 (July 28, 2026).
• NIH Extramural Nexus: release of the U.S. policy for stopping high-risk life-sciences research (July 29, 2026).
• NIH Director statement on the policy (July 2026).
• White House: U.S. Government Policy for Stopping High-Risk Life-Sciences Research (July 2026).
• Executive Order 14292, Improving the Safety and Security of Biological Research (May 5, 2025).
• Senate Homeland Security and Governmental Affairs Committee: testimony of Anthony Fauci (July 29, 2026).
• Office of the Director of National Intelligence: June 2026 Fauci/Wuhan release (official claim source, not a court finding).